Nanophase Technologies CORP 8-K filings

Solsence, Inc. subsidiary Solsence LLC has entered into a settlement agreement with Refy Beauty Ltd, resolving disputes over consumer care products and initiating a six-month exclusivity period for a new SPF product.

Solsence, Inc. announced its first quarter 2026 financial results, highlighting progress on its 'Transform and Transcend' strategic initiative and a focus on operational excellence.

Solsence, Inc. announced the appointment of Marc James as an independent director to its Board, effective April 24, 2026, enhancing board expertise and corporate governance.

Solsence, Inc. announced record full-year 2025 revenue of $62.1 million, alongside strategic initiatives aimed at sustainable, profitable growth.

Solesence, Inc. has finalized a separation agreement with former CEO Jess Jankowski, detailing severance pay, accelerated stock option vesting, and COBRA premium reimbursements.

Solesence, Inc. announced the retirement of former CEO Jess Jankowski from its Board and his transition to a consulting role, while appointing CEO Kevin Cureton as a new Class III Director.

Solsence, Inc. reported a 14% revenue decrease and a net loss in Q3 2025, alongside significant executive leadership changes and operational restructuring aimed at driving future growth and profitability.

Solsence, Inc. announced a confidential settlement agreement resolving product disputes, securing a $675,000 payment from Solarium Brands, LLC.

Solsence, Inc. announces key leadership changes, promoting Kevin Cureton to CEO and appointing Laura Riffner as CFO, as Jess Jankowski transitions to Board Advisor.

Solsence, Inc. announced that its shareholders approved all proposals at the Annual Meeting, including the election of two directors and the 2025 Equity Compensation Plan.

Solsence, Inc. announced robust second quarter 2025 financial results, with revenue increasing 56% to a record $20.4 million and net income reaching $2.7 million, supported by an expanded debt facility and inclusion in Russell Indexes.

Solsence, Inc. announced it filed a Certificate of Correction with the Delaware Secretary of State to add an accent over the first 'e' in its company name, rectifying an inadvertent omission from a previous filing.

Solsence, Inc. has announced amendments to its existing loan agreements, significantly increasing its borrowing capacity from $14.2 million to $23.0 million and extending maturity dates to April 30, 2027, to support strategic objectives and growth.

Solsence, Inc. announced record first quarter 2025 revenue of $14.6 million, a 48% increase compared to the same period in 2024, driven by strong sales across its consumer product suite.

Solesence, Inc., a health care solutions company, has received approval to transfer its listing to the Nasdaq Capital Market, with trading commencing on April 8, 2025, under the ticker symbol SLSN.

Solsence, Inc. announces record fourth quarter and full-year 2024 financial results, with revenue increasing 58% and 40% respectively, and plans to pursue a NASDAQ uplisting in 2025.

Nanophase Technologies Corporation changes its name to Solesence, Inc. to reflect its focus on beauty science and skin health.

Nanophase Technologies Corporation's shareholders approved an amendment to increase the number of authorized common stock shares from 60 million to 95 million.

Nanophase Technologies Corporation held its annual shareholder meeting on December 18, 2024, where directors were elected and the company's auditor was ratified.

Nanophase Technologies announced record third-quarter revenue of $16.9 million and a profit of $3 million, driven by a 171% year-over-year increase in Solsence revenue.

Nanophase Technologies announced record second-quarter revenue of $13 million and a profit of $1.7 million for the first half of 2024, driven by strong growth in its Solsence business.

Nanophase Technologies announced record first-quarter revenue of $9.9 million and a net profit of $0.9 million, marking a significant turnaround from the previous year's loss.

Nanophase Technologies and BASF have reached a settlement, amending their supply agreement and resolving a legal dispute over exclusivity.

Nanophase Technologies reported flat full-year revenue of $37.3 million for 2023, alongside increased net losses, but secured a $6 million financing package and won a major industry award.

Nanophase Technologies has secured $6 million in funding through a convertible preferred stock agreement with Strandler, LLC, an affiliate of its largest shareholder, to support its growth strategy and address recent financial challenges.